Abstract
Neoadjuvant chemotherapy (NACT) is now widely used in the management of locally advanced breast cancer and in patients with relatively large tumors who are interested in breast conservation. Patients who do not have a complete pathologic complete response typically have poorer outcomes compared with patients with a pCR [Rastogi P et al. J Clin Oncol 2008]. This article presents molecular profiling data on residual triple-negative breast cancer after NACT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
